- •Preface
- •Contents
- •List of Abbreviations
- •Antibacterial Agents
- •A. TOPICAL ANTIBIOTICS
- •B. ORAL ANTIBIOTICS
- •C. ANTIBIOTICS FOR SUBCONJUNCTIVAL/INTRAVITREAL INJECTION
- •D. REGIMENS FOR SPECIFIC ORGANISMS
- •E. REGIMENS FOR SPECIFIC CLINICAL ENTITIES
- •7 Dacryocystitis
- •Antifungal Agents
- •A. AGENTS
- •B. SPECIFIC ANTI-FUNGAL REGIMENS
- •2 Molds
- •3 Dimorphic Fungi
- •Antiviral Agents
- •A. TOPICAL
- •B. SYSTEMIC
- •Anti-Parasitic Agents
- •A. PROTOZOA
- •B. HELMINTHS
- •Anti-Glaucoma Agents
- •D. HYPEROSMOLAR AGENTS
- •H. COMBINATION AGENTS
- •I. SPECIFIC REGIMENTS
- •2 Elevated Eye Pressure During Pregnancy
- •Neuro-Ophthalmology
- •A. AGENTS USED IN NEURO-OPHTHALMOLOGY
- •B. SPECIFIC REGIMENS
- •Anti-Inflammatory Agents
- •A. STEROIDAL
- •B. COMBINATION STEROID WITH ANTIBIOTIC
- •C. NONSTEROIDAL
- •D. MISCELLANEOUS
- •Mydriatics, Cycloplegics, and Reversal Agents
- •Lubricants and Viscoelastics
- •A. ARTIFICIAL TEARS, VISCOELASTICS, AND LUBRICATING OINTMENTS
- •Low Viscosity
- •High Viscosity
- •Unknown Viscosity
- •Insert
- •Gels & Ointments
- •Ointments
- •Gels
- •Viscoelastics
- •B. IRRIGATING SOLUTIONS
- •Miscellaneous
- •A. AGENTS FOR RELIEF OF SEASONAL ALLERGIC CONJUNCTIVITIS/OCULAR DISCOMFORT
- •B. OCULAR DECONGESTANTS
- •C. TOPICAL HYPEROSMOLAR AGENTS
- •D. VITAMINS
- •E. ANESTHETIC AGENTS
- •F. HOMEOPATHIC DRUGS
- •G. CAPSULE STAINING ADJUNCTS
- •H. MISCELLANEOUS
- •I. DRUGS FOR HYPHEMA
- •Anti-Angiogenesis Agents
- •Contact Lens Solutions
- •Contact Lens Solution Hypersensitivity
- •Soft Contact Lens Solutions
- •I. LISTING OF SOFT LENS PRODUCTS BY CATEGORY
- •A. Daily Cleaners
- •B. Enzymatic Cleaners
- •C. Daily Protein Removers
- •D. Rewetting/Lubricating Drops
- •E. Oxidation Solutions/Systems
- •F. Saline Solutions
- •G. Combination Solutions
- •II. SOFT LENS PRODUCTS LISTED BY SYSTEM AND MANUFACTURER: NOT ALL PRODUCTS ARE LISTED IN THIS SECTION BECAUSE NOT ALL PRODUCTS BELONG TO A PARTICULAR SYSTEM
- •Rigid Lens Solutions
- •I. LISTING OF RIGID LENS RODUCTS BY CATEGORY
- •A. Daily Cleaners
- •C. Daily Protein Remover
- •D. Oxidation Systems
- •E. Storage and Disinfection
- •F. Wetting/Rewetting
- •G. Combination Solutions
- •APPENDIX 1: TOPICAL ANTIBACTERIAL SPECTRUM
- •APPENDIX 2: A PREPARING FORTIFIED TOPICAL ANTIBIOTICS AND PREPARING ORAL ACETAZOLAMIDE SOLUTION
- •Fortified Bacitracin
- •Fortified Cefazolin
- •Fortified Vancomycin
- •APPENDIX 3: ANTI-FUNGAL ACTIVITY SPECTRUM
- •APPENDIX 4: RENAL DOSING FOR SELECTED DRUGS
- •Cidofovir Dosing in Renal Failure*
- •Famciclovir Dosing in Renal Failure*
- •Foscarnet Dosing in Renal Failure*
- •Intravenous Ganciclovir Dosing in Renal Failure*
- •Oral Ganciclovir Dosing in Renal Failure*
- •Valacyclovir Dosing in Renal Failure*
- •APPENDIX 5: GLAUCOMA MEDICATION PRESERVATIVES
- •APPENDIX 6: TITRATING TOPICAL DROPS FOR CHILDREN
- •Product Index
- •Subject Index
2. Antifungal AgentsP
PRefer to Appendix 3 for activity spectrum of anti-fungal agents
D.J. Rhee et al., Ophthalmologic Drug Guide, 2nd ed., DOI 10.1007/978-1-4419-7621-5_2,
Springer ScienceþBusiness Media, LLC 2011
A. AGENTS |
|
|
|
|
32 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Concentration/Route |
|
|
|
|
Drug |
Trade |
of Admin. |
Usual Dose |
Notes |
||
|
|
|
|
|
|
|
amphotericin BO |
Fungizone |
Soln, 0.15% |
Q 1–6 hrs |
Varies depending on pathogen |
||
|
|
Subconj |
0.8–1.0 mg |
|
|
|
|
|
Intravitreal |
5 mg/0.1 ml |
|
|
|
fluconazoleOb |
|
IV |
0.8–1.0 mg/kg/day |
|
|
|
Diflucan |
PO/IV |
400 mg on day 1, then |
Max daily dose 400 mg |
|||
flucytosineO |
|
|
100–400 mg QD |
|
|
|
Ancobon |
Soln, 1% |
Q 1–6 hrs |
Varies depending on pathogen |
|||
|
|
PO |
50–150 mg/kg in 4 |
Used only as adjunctive treatment; serum levels |
||
itraconazoleb |
|
|
divided doses |
must be followed |
||
Sporanox |
PO |
200 mg QD-BID |
|
|
|
|
ketoconazoleOb |
Nizoral |
PO |
200–400 mg QD |
Take with food |
||
miconazole |
Monistat |
Soln, 1, 2% |
Q 1–6 hrs |
Varies depending on pathogen |
||
|
|
Subconj |
5–10 mg |
|
|
|
|
|
Intravitreal |
10 mg |
|
|
|
natamycin |
Natacyn |
Susp, 5% |
Q 1–6 hrs |
Varies depending on pathogen |
||
voriconazole |
Vfend |
200 mg |
PO BID |
Varies depending on pathogen |
||
|
|
Soln, 1% |
Q 1–6 hrs |
|
|
|
|
|
Intravitreal |
50 mg/0.1 ml |
|
|
|
|
|
|
|
|
|
|
OToxic agent with potential severe side effects – refer to product information and warnings before use. Some side effects listed above.
bDrug has potential to interact with some medications and may precipitate acute ventricular arrythmia (i.e. terfenadine, astemizole, cisapride, triazolam).
Side Effects:
Drug |
Preparation |
Side Effects |
amphotericin BO Soln: |
burning, irritation |
|
|
Subconj: |
local ischemic necrosis, subconjunctival nodule |
|
Intravitreal: |
chemosis, corneal clouding, possible risk of retinal toxicity |
|
Intravenous: we recommend giving in consultation with infectious disease specialist or physician familiar with its use |
|
|
|
(consider a test dose to monitor for severe reaction). Rapid infusion canresult in hypotension, |
|
|
hypokalemia, arrhythmias, and shock. Fever, chills, hypotension, anddyspnea are common. |
|
|
Nephrotoxicity, renal tubular acidosis, electrolyte abnormalities (hypokalemia and hypomagnesemia), |
fluconazoleOb |
|
anemia, headache, nausea, vomiting, malaise, weightloss, phlebitis, thrombocytopenia, mild leukopenia. |
PO: |
GI distress, allergic rash, eosinophillia, Stevens-Johnson syndrome, transaminase elevation, |
|
flucytosineO |
|
thrombocytopenia. Increases concentrations of phenytoin, sulfonylureas, warfarin, and cyclosporine. |
Soln: |
burning, irritation (typically less than amphotericin) |
|
|
PO: |
marrow suppression leading to leukopenia and thrombocytopenia, rash, nausea, vomiting, severe |
itraconazoleb |
|
enterocolitis, hepatotoxicity, renal toxicity, and cardiac arrest. |
PO: |
nausea, vomiting, rash, pruritus, weakness, dizziness, vertigo, pedal edema, paresthesias, impotence, |
|
ketoconazoleOb |
|
loss of libido. |
PO: |
nausea, anorexia, vomiting, allergic rash, pruritus, gynecomastia, decreased libido/impotence, |
|
|
|
hypertension, and fluid retention secondary to concentrations of adrenalcortical steroids, elevated LFTs |
miconazole |
Soln: |
burning, itching, irritation |
|
Subconj: |
generally well tolerated |
natamycin |
Soln: |
less irritating than amphotericin |
voriconazole |
PO: |
visual disturbances, fever, rash, vomiting, nausea, diarrhea, headache transaminase elevation, need to |
|
|
monitor liver function tests |
|
Soln: |
burning, irritation |
OToxic agent with potential severe side effects – refer to product information and warnings before use.Some side effects listed above.
bDrug has potential to interact with some medications and may precipitate acute ventricular arrythmia (i.e. terfenadine, astemizole, cisapride, triazolam).
Antifungal Agents 33
